Summary
Amgen Inc. (AMGN) announced on February 21, 2020, the successful issuance and sale of a significant aggregate principal amount of senior notes across multiple maturities, totaling approximately $4.95 billion in net proceeds. This debt offering includes notes due in 2025, 2027, 2030, 2040, and 2050, with coupon rates ranging from 1.900% to 3.375%. The substantial capital raised indicates Amgen's strategic financial management and potential for future investments in research, development, or acquisitions. The net proceeds, approximately $4.956 billion after fees, will bolster Amgen's liquidity and financial flexibility. The notes are registered under a previously filed Form S-3 registration statement and were issued under an existing indenture with amendments formalized by an officer's certificate. This offering diversifies Amgen's debt maturity profile and secures long-term funding at attractive interest rates, reflecting favorable market conditions and the company's creditworthiness.
Key Highlights
- 1Amgen successfully issued $4.95 billion in aggregate principal amount of senior notes on February 21, 2020.
- 2The offering includes notes with maturities in 2025, 2027, 2030, 2040, and 2050.
- 3Interest rates on the notes range from a low of 1.900% for the 2025 notes to 3.375% for the 2050 notes.
- 4The net proceeds from the offering were approximately $4.956 billion, after deducting discounts and expenses.
- 5The notes are senior unsecured obligations, ranking equally with other existing and future senior unsecured indebtedness.
- 6A 'change in control' triggering event allows noteholders to require Amgen to purchase their notes at 101% of the principal amount plus accrued interest.
- 7The offering was made under an effective Form S-3 registration statement filed on February 10, 2020.